Invest on your own
Build your own portfolio, stock by stock.
We do it for you
Professionally managed portfolios, built and rebalanced for you.
NEW
How we screen every stock
Our halal screening & purification process in 3 minutes
Screeners
Your portfolio
Calculators
TOOL
Check any stock in seconds
Search 11,000+ tickers and see the halal verdict instantly.
Our certifications
Independent proof that every stock and portfolio meets halal standards.
METHODOLOGY
How we screen every stock
Our 5-step halal methodology, in 90 seconds.
Get help
NEW
Halal investing 101
A beginner-friendly intro to investing the halal way.
Plans by product
COMPARE
Find your plan
See every feature side-by-side and pick what fits.
Investors
INVESTORS
Invest in Musaffa
We're building the financial house for 1.9B Muslims. See the deck.
Amarantus Bioscience Holdings Inc. Stock Analysis AMBS
United States Health Care Nano Cap Amarantus BioScience Holdings, Inc. is a biopharmaceutical company, which engages in developing therapeutic products with the potential for orphan drug designation in the areas of neurology, psychiatry, ophthalmology and regenerative medicine, and diagnostics in neurology. The company is headquartered in San Francisco, California. The company went IPO on 2008-09-29. The firm is focused on developing therapeutic product candidates in the areas of neurology, psychiatry, ophthalmology and regenerative medicine. The firm owns or has licenses to various product candidates in the biopharmaceutical healthcare industry. The company has acquired the rights to the engineered skin substitute program (ESS), a regenerative medicine-based approach for treating severe burns with full-thickness autologous skin grown in tissue culture that is being pursued by Company’s wholly owned subsidiary Cutanogen Corporation. The Company’s wholly owned subsidiary MANF Therapeutics, Inc. owns intellectual property rights and licenses from a number of prominent universities related to the development of the therapeutic protein known as mesencephalic astrocyte-derived neurotrophic factor (MANF). MANF Therapeutics, Inc. is developing MANF-based products as treatments for ophthalmological disorders.
Read More Amarantus Bioscience Holdings Inc (AMBS) Chart
Financial Metrics & Statements of Amarantus Bioscience Holdings Inc (AMBS)
FAQ's for Amarantus Bioscience Holdings Inc (AMBS)
- According to Musaffa’s Shariah screening methodology, Amarantus Bioscience Holdings Inc (AMBS) is currently classified as NOT COVERED as of June 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Amarantus Bioscience Holdings Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in Amarantus Bioscience Holdings Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Amarantus Bioscience Holdings Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Amarantus Bioscience Holdings Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Amarantus Bioscience Holdings Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.